Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Authors
Keywords
PI3K, mTORC1/2, Breast cancer, BEZ235, Inhibitor
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 82, Issue 2, Pages 285-298
Publisher
Springer Nature
Online
2018-06-07
DOI
10.1007/s00280-018-3610-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
- (2016) H. S. Rugo et al. ANNALS OF ONCOLOGY
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype
- (2014) Seung-Woo Hong et al. APOPTOSIS
- Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
- (2014) N. A. O'Brien et al. CLINICAL CANCER RESEARCH
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract P6-15-07: A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors
- (2011) J Rodon et al. CANCER RESEARCH
- Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
- (2011) C. Santiskulvong et al. CLINICAL CANCER RESEARCH
- The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
- (2011) Niranjan Awasthi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- (2011) Jatin Roper et al. PLoS One
- NVP-BEZ235 as a New Therapeutic Option for Sarcomas
- (2010) M. C. Manara et al. CLINICAL CANCER RESEARCH
- PI3K and mTOR inhibitors—a new generation of targeted anticancer agents
- (2009) Saskia Brachmann et al. CURRENT OPINION IN CELL BIOLOGY
- Induction of Akt Activity by Chemotherapy Confers Acquired Resistance
- (2009) Wei-Chien Huang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
- (2008) C. R. Schnell et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Critical aspects of the Bayesian approach to phase I cancer trials
- (2008) Beat Neuenschwander et al. STATISTICS IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now